Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • IL-6 Inhibitor Ziltivekimab Increases Serum Hemoglobin and Iron Biomarkers in Patients with CKD Stage 3-5: A RESCUE Trial Analysis

    Journal of the American Society of Nephrology Date published:

  • The TESTING Study: Steroids vs. Placebo in High Risk IgA Nephropathy

    Journal of the American Society of Nephrology Date published:

  • Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

    European Heart Journal Date published:

  • Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial

    Journal of the American Society of Nephrology Date published:

  • Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

    The Lancet Date published:

  • Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program

    Diabetologia Date published:

  • Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

    European Heart Journal Date published:

  • Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis

    Diabetes, Obesity and Metabolism Date published:

  • Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial

    Diabetologia Date published:

  • Rationale, design, demographics, and baseline characteristics of the randomised, controlled, phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia

    Nephrology Dialysis Transplantation Date published:

  • Chronic kidney disease

    The Lancet Date published:

  • Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial

    Clinical Kidney Journal Date published:

  • Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure

    Clinical Journal of the American Society of Nephrology Date published:

  • Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey

    BMJ Open Date published:

  • 129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial

    Diabetes Date published:

  • 131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

    Diabetes Date published: